In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients ...

In urothelial bladder cancer, increased T cell infiltration has been correlated with longer patient survival. Previous clinical studies with an FGFR inhibitor, rogaratinib, demonstrated that the ...

Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed ...

Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time ...

NIH clinical trial results expand treatment options for this disease.

Patients were stratified by visible residual disease at transurethral resection of bladder tumor (TURBT ... Further, 20.3% ...